Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
40 hedge funds and large institutions have $34.4M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
52% more capital invested
Capital invested by funds: $22.7M → $34.4M (+$11.7M)
8% more funds holding
Funds holding: 37 → 40 (+3)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $233K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$183K |
| 2 |
Morgan Stanley
New York
|
+$90.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$42.9K |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$42.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$192K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$68.4K |
| 3 |
Renaissance Technologies
New York
|
-$60.5K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$15.3K |
| 5 |
Barclays
London,
United Kingdom
|
-$10.8K |
ELOX Hedge Fund Activity: Q4 2020 in Review
40 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q4 2020, worth a combined $34.4M — up 52% from $22.7M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ELOX positions and 1 closed out — a net gain of 3 holders — while 15 added to existing stakes and 9 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $183K. The largest seller was Russell Investments Group, cutting an estimated $192K.
- 40 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q4 2020, up from 37 in Q3 2020.
- Funds reported $34.4M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q4 2020, up 52% quarter-over-quarter.
- 4 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q4 2020 and 1 closed out, a net change of +3 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q4 2020 was JP Morgan Chase, an estimated $183K added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q4 2020 was Russell Investments Group, an estimated $192K sold.
Based on aggregated 13F filings for Q4 2020.